Allergan plc stated that they own a 36.3% stake in Tobira Therapeutics Inc. (NASDAQ:TBRA) in a Schedule 13D disclosure that was filed with the Securities and Exchange Commission on Thursday, September 29th. The investor owns 6,838,661 shares of the stock worth about $270,058,723. The reporting parties listed on the disclosure included Allergan plc, Allergan Holdco US, Inc and Sapphire Acquisition Corp. The disclosure is available through the SEC website at this link.
Several other institutional investors also recently added to or reduced their stakes in TBRA. Geode Capital Management LLC boosted its position in Tobira Therapeutics by 2.5% in the first quarter. Geode Capital Management LLC now owns 32,223 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 799 shares during the period. Franklin Resources Inc. purchased a new position in Tobira Therapeutics during the first quarter worth $4,797,000. State Street Corp boosted its position in Tobira Therapeutics by 184.3% in the first quarter. State Street Corp now owns 42,875 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 27,794 shares during the period. Teachers Advisors Inc. boosted its position in Tobira Therapeutics by 287.1% in the second quarter. Teachers Advisors Inc. now owns 14,484 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 10,742 shares during the period. Finally, TFS Capital LLC purchased a new position in Tobira Therapeutics during the second quarter worth $533,000. 62.02% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) traded up 0.18% during mid-day trading on Thursday, hitting $39.49. 78,578 shares of the stock were exchanged. Tobira Therapeutics Inc. has a 12 month low of $3.76 and a 12 month high of $41.39. The stock’s market cap is $743.24 million. The company has a 50-day moving average price of $11.66 and a 200-day moving average price of $9.62.
Tobira Therapeutics (NASDAQ:TBRA) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.08. The firm earned $1.06 million during the quarter. Equities analysts expect that Tobira Therapeutics Inc. will post ($2.65) earnings per share for the current year.
A number of research firms have weighed in on TBRA. Zacks Investment Research cut shares of Tobira Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. Cantor Fitzgerald cut shares of Tobira Therapeutics to a “buy” rating and set a $19.00 price objective on the stock. in a research report on Monday, July 25th. HC Wainwright reiterated a “buy” rating on shares of Tobira Therapeutics in a research report on Tuesday, June 28th. Mizuho reiterated a “buy” rating and set a $305.00 price objective on shares of Tobira Therapeutics in a research report on Thursday, September 22nd. Finally, Cowen and Company reiterated a “buy” rating and set a $11.00 price objective on shares of Tobira Therapeutics in a research report on Wednesday, August 10th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Tobira Therapeutics currently has an average rating of “Buy” and a consensus target price of $68.63.
In other Tobira Therapeutics news, major shareholder A/S Novo sold 59,067 shares of the firm’s stock in a transaction on Wednesday, July 13th. The stock was sold at an average price of $12.02, for a total value of $709,985.34. Following the completion of the sale, the insider now directly owns 1,914,541 shares of the company’s stock, valued at approximately $23,012,782.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Pentwater Capital Management L bought 100,000 shares of the business’s stock in a transaction on Friday, September 23rd. The stock was bought at an average cost of $39.19 per share, with a total value of $3,919,000.00. The disclosure for this purchase can be found here. 6.20% of the stock is owned by company insiders.
About Tobira Therapeutics
Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.
Want to see what other hedge funds are holding TBRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tobira Therapeutics Inc. (NASDAQ:TBRA).
Receive News & Ratings for Tobira Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.